Lecap Asset Management Ltd. Makes New $1.51 Million Investment in Insulet Co. (NASDAQ:PODD)

Lecap Asset Management Ltd. bought a new position in shares of Insulet Co. (NASDAQ:PODD - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 6,959 shares of the medical instruments supplier's stock, valued at approximately $1,510,000.

A number of other hedge funds also recently made changes to their positions in PODD. First Manhattan Co. bought a new stake in Insulet in the 4th quarter valued at about $35,000. Wolff Wiese Magana LLC raised its stake in Insulet by 2,680.0% in the 4th quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier's stock valued at $30,000 after acquiring an additional 134 shares during the period. Parkside Financial Bank & Trust raised its stake in Insulet by 251.0% in the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier's stock valued at $27,000 after acquiring an additional 123 shares during the period. Allworth Financial LP raised its stake in Insulet by 104.5% in the 3rd quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 92 shares during the period. Finally, BluePath Capital Management LLC bought a new stake in Insulet in the 3rd quarter valued at about $31,000.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on PODD shares. JPMorgan Chase & Co. lifted their target price on Insulet from $190.00 to $225.00 and gave the company an "overweight" rating in a report on Friday, February 23rd. Robert W. Baird raised Insulet from a "neutral" rating to an "outperform" rating and lifted their target price for the company from $180.00 to $238.00 in a report on Thursday, December 21st. Piper Sandler reduced their target price on Insulet from $250.00 to $230.00 and set an "overweight" rating for the company in a report on Friday, February 23rd. Stifel Nicolaus lifted their target price on Insulet from $163.00 to $208.00 and gave the company a "hold" rating in a report on Monday, February 5th. Finally, Barclays reduced their target price on Insulet from $214.00 to $213.00 and set an "equal weight" rating for the company in a report on Monday, February 26th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $250.33.

Insider Activity at Insulet

In related news, Director Shacey Petrovic sold 11,609 shares of the company's stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the completion of the transaction, the director now owns 2,567 shares in the company, valued at $418,215.64. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.90% of the stock is owned by corporate insiders.

Insulet Price Performance

PODD traded down $4.43 during midday trading on Friday, hitting $175.22. The stock had a trading volume of 680,529 shares, compared to its average volume of 725,251. The company has a market cap of $12.27 billion, a P/E ratio of 60.21, a price-to-earnings-growth ratio of 3.23 and a beta of 0.98. The business has a fifty day moving average of $176.72 and a 200 day moving average of $178.71. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. Insulet Co. has a 1 year low of $125.82 and a 1 year high of $335.91.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.73. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The firm had revenue of $509.80 million during the quarter, compared to the consensus estimate of $461.26 million. During the same quarter in the previous year, the company posted $0.55 earnings per share. The business's revenue was up 37.9% on a year-over-year basis. As a group, equities analysts forecast that Insulet Co. will post 3.08 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.